2025
The role of long non-coding ribonucleic acid HOXA11-AS in endometriosis therapy
Mamillapalli R, Gawde N, Fay M, Atwani R, Moridi I, Taylor H. The role of long non-coding ribonucleic acid HOXA11-AS in endometriosis therapy. Reproductive Biology And Endocrinology 2025, 23: 83. PMID: 40457415, PMCID: PMC12128536, DOI: 10.1186/s12958-025-01420-0.Peer-Reviewed Original ResearchConceptsHOXA11-ASHOXA11-AS expressionEutopic endometriumLong non-coding RNAsEctopic endometriotic lesionsEndometriotic cell linesInvasion of endometriosisEndometrial stromal cellsReal-time polymerase chain reactionNon-coding RNAsEndometriotic lesionsEndometriosis therapyEndometriosis patientsNormal endometriumProgestin responsivenessEndometrial developmentTreatment responsePolymerase chain reactionQuantitative real-time polymerase chain reactionEndometriosisEndometriosis treatmentMethodsTissue samplesStromal cellsPotential target genesEndometrium
2024
Mood lability and depression limit oral contraceptive therapy in endometriosis
Cevik E, Taylor H. Mood lability and depression limit oral contraceptive therapy in endometriosis. Fertility And Sterility 2024, 123: 838-845. PMID: 39672361, DOI: 10.1016/j.fertnstert.2024.12.011.Peer-Reviewed Original ResearchProgestin-only oral contraceptivesOral contraceptivesOC discontinuationOC useDiagnosis of depressionMood labilityEffects of oral contraceptivesOral contraceptive (OCDocumented diagnosis of depressionDiscontinued OC useEffect of OC useInternational Classification of Diseases-10 codesSide effects of OC useElectronic medical record reviewTreated with OCCourse of treatmentMedical record reviewIncreased incidence of depressionUniversity affiliated hospitalTreatment discontinuationIncidence of depressionEndometriosisStudy cohortPrimary outcomeIncreased incidenceWomen with endometriosis in the United States: National Survey of Family Growth, 2011–2019
Al-Lami R, Taha S, Jalloul R, Taylor H. Women with endometriosis in the United States: National Survey of Family Growth, 2011–2019. Journal Of Endometriosis And Uterine Disorders 2024, 8: 100081. DOI: 10.1016/j.jeud.2024.100081.Peer-Reviewed Original ResearchNational Survey of Family GrowthAssociated with infertilityFamily GrowthRates of functional impairmentQuality of lifeNational surveyWeighted prevalencePrevalence of infertilityPain associated with endometriosisLongitudinal population-based studyAssociated with endometriosisPrevalence of endometriosisFunctional impairmentNationally representative samplePopulation-based studyDiminished quality of lifeLogistic regression analysisSample of womenCross-sectional studyCharacteristics of womenInfertile womenEndometriosisReproductive factorsU.S. womenAnalytic sampleTET3-overexpressing macrophages promote endometriosis
Lv H, Liu B, Dai Y, Li F, Bellone S, Zhou Y, Mamillapalli R, Zhao D, Venkatachalapathy M, Hu Y, Carmichael G, Li D, Taylor H, Huang Y. TET3-overexpressing macrophages promote endometriosis. Journal Of Clinical Investigation 2024, 134: e181839. PMID: 39141428, PMCID: PMC11527447, DOI: 10.1172/jci181839.Peer-Reviewed Original ResearchDisease-associated macrophagesTET3 overexpressionHuman endometriosis lesionsPathophysiology of endometriosisPro-inflammatory cytokine productionChronic inflammatory diseaseReproductive age womenEndometriosis lesionsE3 ubiquitin ligasePathogenic macrophagesCytokine productionEndometriosisInflammatory diseasesTET3 knockdownEndometriosis progressionPathogenic contributorsLet-7 miRNA expressionAge womenMacrophagesMouse macrophagesTherapeutic targetUbiquitin ligaseTET3MiceDiseaseIs There an Association Between Endometriosis, Early Menopause, and Cardiovascular Disease?
Younis J, Taylor H. Is There an Association Between Endometriosis, Early Menopause, and Cardiovascular Disease? The Journal Of Clinical Endocrinology & Metabolism 2024, 109: e1946-e1949. PMID: 39083665, DOI: 10.1210/clinem/dgae508.Peer-Reviewed Original ResearchEarly menopauseEndometriotic cystectomyNatural menopauseCardiovascular riskCardiovascular diseaseEndometriosis-associated pelvic painIncreased risk of cardiovascular diseaseLaparoscopically diagnosed endometriosisRisk of cardiovascular diseaseEarly natural menopauseLarge-scale cohort studyPelvic painOvarian reserveBilateral casesMenopause onsetMultiple surgeriesEndometriosisCohort studyHazard ratioIncreased riskMenopauseCystectomyRisk factorsEstimates of associationConfounding factorsMedical Management of Endometriosis in Adolescent and Young Adult Women: A Review of 91 Cases of Biopsy-Confirmed Endometriosis
Li H, Esencan E, Song Y, Taylor H, Cho Y, Vash-Margita A. Medical Management of Endometriosis in Adolescent and Young Adult Women: A Review of 91 Cases of Biopsy-Confirmed Endometriosis. Journal Of Obstetrics And Gynaecology Canada 2024, 46: 102562. PMID: 38759792, DOI: 10.1016/j.jogc.2024.102562.Peer-Reviewed Original ResearchCombined oral contraceptivesBiopsy-proven endometriosisLNG-IUDManagement of endometriosisOral progestinInitial treatmentRetrospective chart review of womenChart review of womenMedical management of endometriosisProgestin-only formulationsLevonorgestrel intrauterine deviceReview of womenRetrospective chart reviewYoung adult patientsTertiary hospital systemPelvic painIntrauterine deviceOral contraceptivesTreatment regimensYounger patientsAdult patientsHormonal managementEndometriosisTreatment planningCurrent treatmentVilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial
Taylor H, Dong L, Haikonen J, Oppelt P, Tamussino K, Wenzl R, Faustmann T, Groettrup-Wolfers E, Ren X, Seitz C. Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial. F&S Reports 2024, 5: 189-196. PMID: 38983729, PMCID: PMC11228778, DOI: 10.1016/j.xfre.2024.03.002.Peer-Reviewed Original ResearchPelvic painSymptomatic endometriosisTreatment of symptomatic endometriosisEndometriosis-associated pelvic painBaseline to month 3Use of pain medicationAverage pain scoreMonths of treatmentPhase 2b randomized controlled trialAssess treatment effectsOutcome measures Primary outcomesPlacebo recipientsRandomized controlled trialsPain scoresMonth 3Pain medicationIncreased painVilaprisanPlaceboPrimary outcomeEndometriosisToxicity findingsIntervention participantsClinical relevanceBleeding intensity
2023
CHARACTERIZATION OF PROGESTERONE RESISTANCE IN A PROSPECTIVE COHORT OF SURGICALLY CONFIRMED PATIENTS WITH OR WITHOUT ENDOMETRIOSIS
Singh B, Courtright L, Brennan J, Chen L, Wu H, Patzkowsky K, Wang K, Simpson K, Wang T, Shih I, Cope L, Schepisi L, Taylor H, Segars J. CHARACTERIZATION OF PROGESTERONE RESISTANCE IN A PROSPECTIVE COHORT OF SURGICALLY CONFIRMED PATIENTS WITH OR WITHOUT ENDOMETRIOSIS. Fertility And Sterility 2023, 120: e224. DOI: 10.1016/j.fertnstert.2023.08.639.Peer-Reviewed Original ResearchClinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine
Saleh F, Taylor H. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine. F&S Reports 2023, 4: 83-87. PMID: 37223759, PMCID: PMC10201293, DOI: 10.1016/j.xfre.2023.01.008.Peer-Reviewed Original ResearchHormone analogueGonadotropin-releasing hormone analogueOral GnRH antagonistCommon gynecologic conditionOvarian hormone productionClinical applicationGnRH antagonistPituitary responseGnRH activityGnRH analoguesGynecologic conditionsTreatment optionsGonadal axisReproductive axisRapid onsetGynecologic practiceHormone productionReproductive medicineReproductive technologiesDiverse clinical applicationsGonadotropinEndometriosisFibroidsGnRHAntagonistEpidemiologic and Genetic Associations of Endometriosis With Depression, Anxiety, and Eating Disorders
Koller D, Pathak G, Wendt F, Tylee D, Levey D, Overstreet C, Gelernter J, Taylor H, Polimanti R. Epidemiologic and Genetic Associations of Endometriosis With Depression, Anxiety, and Eating Disorders. JAMA Network Open 2023, 6: e2251214. PMID: 36652249, PMCID: PMC9856929, DOI: 10.1001/jamanetworkopen.2022.51214.Peer-Reviewed Original ResearchConceptsPsychiatric comorbidityMAIN OUTCOMEMental healthIrritable bowel syndromeBody mass indexAssociation of endometriosisOdds of depressionSevere physical symptomsPain-related phenotypesWomen's mental healthMultivariate regression analysisOdds of endometriosisBowel syndromeGenetic associationMass indexGynecologic pathologyMillion Veteran ProgramEndometriosisPsychiatric disordersWomen's healthFemale controlsPleiotropic mechanismsPhysical symptomsComorbiditiesFinnGen study
2022
Endometriosis-associated infertility: From pathophysiology to tailored treatment
Bonavina G, Taylor H. Endometriosis-associated infertility: From pathophysiology to tailored treatment. Frontiers In Endocrinology 2022, 13: 1020827. PMID: 36387918, PMCID: PMC9643365, DOI: 10.3389/fendo.2022.1020827.Peer-Reviewed Original ResearchConceptsEndometriosis-associated infertilityRole of surgeryCurrent treatment optionsNon-invasive diagnostic toolLevel of impairmentInfertile womenRelated infertilityEndometrial receptivitySystemic diseaseTreatment optionsClinical managementDysfunctional alterationsEndometriosisSystemic effectsClinical situationsInfertilityPelvic anatomyClinical settingEndometriosis subtypesPrecise diagnosisPatient phenotypesReproductive technologiesDiagnostic toolTreatmentPhenotypePre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial
Taylor H, Li HJ, Carson S, Flores V, Pal L, Robbins J, Santoro NF, Segars JH, Seifer D, Huang H, Young S, Zhang H. Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial. BMJ Open 2022, 12: e052043. PMID: 35715184, PMCID: PMC9207753, DOI: 10.1136/bmjopen-2021-052043.Peer-Reviewed Original ResearchConceptsEndometriosis-associated infertilityPlacebo-controlled trialGnRH antagonistFertility treatmentOral GnRH antagonistEndometriosis-related infertilityFertilization-embryo transferLive birth rateUse of gonadotropinsEtiology of infertilityInstitutional review boardAntagonist pretreatmentCommon complicationObstetrical outcomesPeer-reviewed journalsSecondary outcomesIVF treatmentPrimary outcomeHormone agonistImplantation ratePregnancy rateLive birthsEndometriosisLocal protocolsOocyte number
2021
Reimagining Endometriosis
Taylor HS. Reimagining Endometriosis. Med 2021, 2: 481-485. PMID: 35590229, DOI: 10.1016/j.medj.2021.04.026.Peer-Reviewed Original ResearchTofacitinib alters STAT3 signaling and leads to endometriosis lesion regression
Kotlyar AM, Mamillapalli R, Flores VA, Taylor HS. Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression. Molecular Human Reproduction 2021, 27: gaab016. PMID: 33693775, PMCID: PMC8454207, DOI: 10.1093/molehr/gaab016.Peer-Reviewed Original ResearchConceptsLesion regressionIshikawa cellsJAK/STATGrowth factor mRNA levelsEffects of tofacitinibTreatment of endometriosisHypoxia-inducible factor-1αVascular endothelial growth factor (VEGF) mRNA levelsFactor mRNA levelsWidespread clinical useWestern blot analysisVehicle treatmentOral gavageGynecologic conditionsC57BL/6 miceEutopic endometriumJanus kinase/signal transducerReproductive ageEndometriosisJAK inhibitorsKinase/signal transducerTofacitinibTherapeutic targetLesion growthClinical useEndometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling
Chen P, Mamillapalli R, Habata S, Taylor HS. Endometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling. Molecular And Cellular Biochemistry 2021, 476: 1717-1727. PMID: 33428059, DOI: 10.1007/s11010-020-04012-1.Peer-Reviewed Original ResearchConceptsPD-1 expressionPD-1Stromal cellsT-cell PD-1 expressionEndometriosis stromal cellsGrowth of endometriosisPD-1 inductionDifferentiation of BMDCsBone marrow mesenchymal stem cell differentiationT cell quiescenceBMDC differentiationImmune toleranceEndometriosis patientsEndometriotic lesionsNormal endometriumEndometrial cellsEndometriosis cellsGynecological disordersImmune surveillanceMurine modelBMDCsEndometriosisLesion sizeCXCR4 receptorLesions
2020
Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatientsCorrigendum to “Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis” [Reprod. Biol. 18 (2018) 109–114]
Hufnagel D, Goetz LG, Hu Z, Nyachieo A, D'Hooghe T, Fazleabas A, Duleba A, Krikun G, Taylor HS, Lockwood CJ. Corrigendum to “Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis” [Reprod. Biol. 18 (2018) 109–114]. Reproductive Biology 2020, 20: 600. PMID: 32900640, DOI: 10.1016/j.repbio.2020.08.005.Peer-Reviewed Original ResearchReal-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
Surrey ES, Soliman AM, Johns B, Vora JB, Taylor HS, Agarwal SK. Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database. ClinicoEconomics And Outcomes Research 2020, 12: 473-479. PMID: 32922052, PMCID: PMC7456657, DOI: 10.2147/ceor.s264905.Peer-Reviewed Original ResearchEndometriosis Cell Proliferation Induced by Bone Marrow Mesenchymal Stem Cells
Chen P, Mamillapalli R, Habata S, Taylor HS. Endometriosis Cell Proliferation Induced by Bone Marrow Mesenchymal Stem Cells. Reproductive Sciences 2020, 28: 426-434. PMID: 32812213, DOI: 10.1007/s43032-020-00294-4.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCase-Control StudiesCDC2 Protein KinaseCell ProliferationCells, CulturedCoculture TechniquesDisease Models, AnimalEndometriosisEndometriumFemaleHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMice, Inbred C57BLParacrine CommunicationSignal TransductionStromal CellsConceptsBone marrow-derived stem cellsCell proliferationEndometrial cellsEstrogen-dependent gynecological disorderPrimary endometrial stromal cellsEndometrial stromal cell proliferationEndometriosis cell proliferationReproductive-aged womenEndometrial stromal cellsNormal endometrial cellsEndometrial cell proliferationMarrow-derived stem cellsNovel therapeutic strategiesStromal cell proliferationBone marrow mesenchymal stem cellsStem cellsSignificant clonal expansionMarrow mesenchymal stem cellsPelvic painEndometriotic lesionsEndometriosis growthGynecological disordersEndometriosis cell linesMouse modelEndometriosisHealth-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
Taylor HS, Soliman AM, Johns B, Pokrzywinski RM, Snabes M, Coyne KS. Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix. Obstetrics And Gynecology 2020, 136: 501-509. PMID: 32769633, PMCID: PMC7431150, DOI: 10.1097/aog.0000000000003917.Peer-Reviewed Original ResearchConceptsResponder definitionPlacebo groupSevere painSexual intercourseEHP-30 questionnaireMeaningful HRQoL improvementsPercentage of patientsPhase III trialsHealth-related qualityPoisson regression analysisSocial supportHRQoL improvementIII trialsMonth 6Month 3EHP-30Months 1Baseline scoresElagolixPainPatientsMeaningful improvementsEndometriosisPlaceboRegression analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply